Biotech Analyst Suvannavejh discusses the Intellectual Property (IP) matters in the Biotech/Biopharma Industries, a review of the IP estate for AXSM‘s lead asset, Auvelity/AXS-05 and the February 2023 Paragraph IV ANDA filing by TEVA for a generic Auvelity on an Analyst/Industry conference call to be held on July 26 at 12 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Mizuho biotech/biopharma analyst to hold analyst/industry conference call
- Axsome Therapeutics price target lowered to $190 from $200 at H.C. Wainwright
- Short Report: Bearishness on BioXcel at record high amid trial conduct review
- William Blair biotech analyst to hold an analyst/industry conference call
- Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7